CYFRA 21-1 and CEA are independent prognostic factors in 153 operated stage I NSCLC patients

Anticancer Research

Volumn 24, Issue 3 B, 2004, Pages 1953-1956

  Muley, Thomas ^a   Dienemann, Hendrik ^a   Ebert, Werner ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

CEA; CYFRA 21 1; NSCLC

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CELL PROTEIN; CYTOKERATIN 19 FRAGMENT; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER RISK; CANCER STAGING; CANCER SURGERY; CONFIDENCE INTERVAL; FEMALE; GEOMETRY; HIGH RISK POPULATION; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL ANALYSIS; MULTIVARIATE ANALYSIS; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; STATISTICAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME; TREATMENT PLANNING; TUMOR MARKER INDEX;

ADULT; AGED; ANTIGENS, NEOPLASM; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; KERATINS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 3242725210     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Dienemann H: Principles of surgical treatment in localized non-small cell lung cancer. Lung Cancer 33 Suppl. 1: S3-S8, 2001.
2. Zielinski CC et al: Consensus on medical treatment of non-small cell lung cancer. Lung Cancer 38: S3-S7, 2002.
3. Brundage MD, Davies D and Mackillop MB: Prognostic factors in non-small cell lung cancer - A decade of progress. Chest 122: 1037-1057, 2002.
4. Pujol J-L, Boher J-M, Grenier J and Quantin X: CYFRA 21-1, neuron specific enolase and prognosis of non-small cell lung cancer: prospective study in 621 patients. Lung Cancer 31: 221-231, 2001.
5. Niklinski J, Burzykowski T, Niklinska W et al: Preoperative CYFRA 21-1 level as a prognostic indicator in resected non-small cell lung cancer. Eur Resp J 12: 1424-1428, 1998.
6. Nisman B, Lafair J, Heching N et al: Evaluation of tissue polypeptide specific antigen, CYFRA21-1, and carcinoembryonic antigen in non-small cell lung carcinoma: does the combined use of cytokeratin markers give any additional information? Cancer 82: 1850-1859, 1998.
7. Muley T, Dienemann H and Ebert W: Increased CYFRA 21-1 and CEA levels are negative predictors of outcome in p-stage I NSCLC. Anticancer Res 23: 4085-4094, 2003.
8. World Health Organization: Histological Classification of Lung Tumors. WHO, Geneva, 1981.
9. Mountain CF: Revisions in the international item for staging lung cancer. Chest 111: 1710-1717, 1997.
10. Abel U, Berger S and Wiebelt H: Critlevel. An exploratory procedure for the evaluation of quantitative prognostic factors. Methods Inf Med 23: 154-156, 1984.
11. Kaplan EL and Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958
12. Cox Dr: Regression models and life tables (with discussion). J R Stat Soc 34: 187-220, 1972.
13. Kulpa J, Wojcik E, Reinfuss M and Kolodziejski L: Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21-1, and neuron-specific enolase in squamous cell lung cancer patients. Clin Chem 48: 1931-1937, 2002.
14. Nisman B, Amir G, Lafair J, Heching N, Lyass O, Peretz T and Barak V: Prognostic value of CYFRA 21-1, TPS and CEA in different histologic types of non-small cell lung cancer. Anticancer Res 19: 3549-3552, 1999.
15. Reinmuth N, Brandt B, Semik M, Kunze W-P, Achatzky R, Scheld HH, Broermann P, Berdel WE, Macha HN and Thomas M: Prognostic impact of CYFRA 21-1 and other serum markers in completely resected non-small cell lung cancer. Lung Cancer 36: 265-270, 2002.
16. Suzuki K, Nagai K, Yoshida MD et al: Prognostic factors in clinical stage I non-small cell lung cancer. Ann Thorac Surg 67: 927-932, 1999.
17. Sawabata N, Otha M, Takeda SI, Hirano H, Okumura Y, Asada H and Maeda H: Serum carcinoembryonic antigen level in surgically resected clinical stage I patients with non-small cell lung cancer. Ann Thorac Surg 74: 174-179, 2002.